Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
AACR, abrupt, absorb, adjournment, adoptedEITF, AIG, Alastair, alive, andEITF, angina, appoint, appointed, appointment, ARB, ARVO, attestation, autoimmune, backbone, bailout, beneficiary, bid, Biennial, billion, biomarker, bond, brain, cardiovascular, cast, cease, classification, colon, constantly, constrast, consummation, cooperative, corroborate, cytoskeleton, cytoxic, degradation, departure, depolymerization, doubt, drawdown, earliest, Edelman, elevated, encumber, engineering, enjoy, enterprise, enzyme, Eric, exceed, exited, expert, facto, FALCON, fall, fatigue, ForceNo, fragile, hand, headache, Hedging, hepatic, hierarchy, hypertension, Iceland, illustrated, ImClone, immature, indeterminable, ineffective, Intermittently, invasive, invoiced, IRC, ischemia, JDC, journalSciencethat, journalThyroid, judgment, Kessel, kidney, Liechtenstein, lieu, liver, LLC, LP, lymph, mandate, mandatory, meaningfully, moderately, monthly, mutually, myeloid, myocardial, Myriad, nausea, NCE, nephrotic, neurodegenerative, Nicole, node, noncontrolling, nonfinancial, Novated, Obama, obviate, occlude, officially, ofnew, OMX, Onetto, ophthamology, orthoquinone, ovary, oversee, overseen, oxidative, Oxley, pain, panel, payer, pegaptanib, perforation, Policiesunder, poorly, proportionate, proteinuria, quorum, quoted, ranibizumab, rata, ratified, rationale, rectum, Reinvestment, remeasured, Remick, representation, residual, resignation, robust, Rowinsky, RRD, satisfaction, scenario, Scot, Seperately, skin, smaller, solicit, sorafenib, spending, standing, straightforward, sublet, subordinated, sunitinib, Symphony, syndrome, theexistingblood, thromboembolic, transaction, transient, treatement, unconfirmed, unfair, unobservable, unproven, unresponsive, USAN, variability, variable, vascularly, vi, vida, VIE, vii, viii, vomiting, Wood, worth, ZBYRESTAT, ZYBERESTAT, ZYBRETAT
Removed:
Abbott, acceptance, accurately, adjacent, Adjunct, Aeterna, affordable, African, AG, ago, aimed, Akerley, alternate, Army, assessed, Assistant, attacking, author, authored, bark, Bayer, Beth, biology, Biomolecular, Birmingham, blockade, broadened, Brook, bush, caffrum, cancelled, carcinoma, certainty, charity, Citron, Cleveland, cohort, coincided, compatibility, compound, compromising, conditioned, Conference, conform, conventional, core, curing, damage, decade, deducting, deduction, define, delivery, deprive, desire, detect, detection, discovered, Disposal, disposition, distinguishable, Division, dosed, dramatic, Dutch, editorial, efficient, elongated, emerge, Emission, enhance, EntreMed, EORTC, equivalent, ESMO, esophageal, evaluable, examined, experimental, expired, Fabre, family, fighting, focal, focused, focusing, forward, found, foundation, Genentech, germ, GlaxoSmithKline, Gray, grow, guarantee, Harvard, hematology, hire, Honorary, Huntsman, immunotherapy, incurable, induce, innovation, inoperable, insight, instructorship, instrumentation, intact, Integrated, integrity, internationally, internship, invest, investigate, investigated, Ireland, isolated, Israel, Johnson, journal, kill, landlord, larger, leading, leased, lectured, led, Magdalen, Magnetic, matching, metastasized, Middlesex, Millennium, mode, moved, narrow, naturally, NeoPharm, newer, Oak, offering, OM, OQP, ordinarily, ostensibly, owed, performing, peripheral, periphery, persist, pertain, Pfizer, Pharmacodynamic, Pharmacology, Pierre, placement, point, Positron, postgraduate, preclinical, prevalent, prodrug, Professorship, progressed, progressive, projected, promissory, prostate, pursued, Radiumhemmet, recently, recipient, reclassified, regrowth, relocated, renal, reoccupy, researching, reside, residency, resistance, Resonance, rim, Robinson, scientist, Secretary, served, settlement, shutting, signal, stated, stream, subtenant, suitable, summarized, surgical, surviving, targeting, Tempe, termed, Throughin, today, tomography, training, transitional, trend, triple, UCLA, unamortized, undiscounted, unqualified, Utah, vital, vitroandin, vivotesting, vote, Wallace, weekly, willow, worldwide, Zecher
Filing tables
Filing exhibits
- 10-K Annual report
- 10.51 EX-10.51 409A Amendment to Employment Agreement MR. Chaplin
- 10.52 EX-10.52 409A Amendment to Employment Agreement MR. Kollins
- 10.53 EX-10.53 409A Amendment to Employment Agreement MR. Murphy
- 10.54 EX-10.54 409A Amendment to Employment Agreement DR. Walicke
- 10.55 EX-10.55 Amendment No 2 to Employment Agreement DR. Chaplin
- 10.56 EX-10.56 Amendment No 2 to Employment Agreement MR. Murphy
- 10.57 EX-10.57 Research and Development Agreement Vida Holdings
- 10.58 EX-10.58 Amended and Restated Research and Development Agreement Vida Holdings
- 10.59 EX-10.59 Lease
- 23 EX-23 Consent of Ernst & Young LLP
- 31.1 EX-31.1 Section 302 Cert of CEO
- 31.2 EX-31.2 Section 302 Cert of CFO
- 32 EX-32 Section 906 Cert of CEO and CFO
Related press release
OTLC similar filings
Filing view
External links
Exhibit 23
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
1. | Registration Statements (Form S-3 Nos. 333-155372, 333-155371, 333-128528, 333-106307 and 333-109433) of OXiGENE, Inc., |
2. | Registration Statement (Form S-8 No. 333-05787) pertaining to the Amended and Restated Stock Incentive Plan of OXiGENE, Inc., |
3. | Registration Statements (Form S-8 Nos. 333-92747, 333-32958 and 333-117083) pertaining to the 1996 Stock Incentive Plan of OXiGENE, Inc., |
4. | Registration Statement (Form S-8 No. 333-84870) pertaining to the Compensation Award Stock Agreements Between Registrant and Certain Directors of OXiGENE, Inc., |
5. | Registration Statement (Form S-8 No. 333-85860) pertaining to the Compensation Award Stock Agreement Between Registrant and a certain Director of OXiGENE, Inc., |
6. | Registration Statement (Form S-8 No. 333-84872) pertaining to the Restricted Stock Agreements Between Registrant and Certain Employees and Non-Employees of OXiGENE, Inc. and, |
7. | Registration Statement (Form S-8 No. 333-126636) pertaining to the 2005 Stock Plan of OXiGENE, Inc.; |
and in the related Prospectuses of our report dated March 26, 2009, with respect to the consolidated financial statements of OXiGENE, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2008.
/s/ Ernst & Young LLP | ||
Boston, Massachusetts | ||
March 26, 2009 |